 Nes-Ziona, Israel, Feb. 24, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of an aggregate of 1,000,000 ordinary shares of the Company at a purchase price of 8.00 per share. H.C. Wainwright Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering, before deducting the placement agents fees and other estimated offering expenses payable by the Company, are expected to be 8.0 million. 